[{"address1": "200 Arsenal Yards Boulevard", "address2": "Suite 230", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 184, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 75000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1075600, "exercisedValue": 457971, "unexercisedValue": 20455824}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 671200, "exercisedValue": 249766, "unexercisedValue": 5641756}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 614498, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 65, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 640345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723600, "exercisedValue": 0, "unexercisedValue": 4995031}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 37.42, "open": 38.37, "dayLow": 36.19, "dayHigh": 38.9, "regularMarketPreviousClose": 37.42, "regularMarketOpen": 38.37, "regularMarketDayLow": 36.19, "regularMarketDayHigh": 38.9, "payoutRatio": 0.0, "beta": 2.188, "forwardPE": -11.850483, "volume": 302966, "regularMarketVolume": 302966, "averageVolume": 489462, "averageVolume10days": 477720, "averageDailyVolume10Day": 477720, "bid": 26.64, "ask": 46.93, "bidSize": 2, "askSize": 2, "marketCap": 2386925056, "fiftyTwoWeekLow": 29.24, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 27.259516, "fiftyDayAverage": 40.3427, "twoHundredDayAverage": 41.75035, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1961777536, "profitMargins": -1.91261, "floatShares": 42699097, "sharesOutstanding": 64765300, "sharesShort": 7690384, "sharesShortPriorMonth": 8772474, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1187, "heldPercentInsiders": 0.013049999, "heldPercentInstitutions": 1.11322, "shortRatio": 14.94, "shortPercentOfFloat": 0.13260001, "impliedSharesOutstanding": 64765300, "bookValue": 13.791, "priceToBook": 2.672395, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -167474000, "trailingEps": -2.34, "forwardEps": -3.11, "enterpriseToRevenue": 22.404, "enterpriseToEbitda": -10.299, "52WeekChange": -0.10564053, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 36.855, "targetHighPrice": 97.0, "targetLowPrice": 41.0, "targetMeanPrice": 58.84211, "targetMedianPrice": 57.0, "recommendationMean": 1.55, "recommendationKey": "buy", "numberOfAnalystOpinions": 19, "totalCash": 549969984, "totalCashPerShare": 8.492, "ebitda": -190490000, "totalDebt": 88231000, "quickRatio": 8.286, "currentRatio": 8.548, "totalRevenue": 87563000, "debtToEquity": 9.881, "revenuePerShare": 1.258, "returnOnAssets": -0.15378, "returnOnEquity": -0.25996, "grossProfits": -133838000, "freeCashflow": -94098128, "operatingCashflow": -124672000, "revenueGrowth": -0.209, "grossMargins": -1.52848, "ebitdaMargins": -2.17546, "operatingMargins": -19.279339, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketTime": 1740171254, "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "regularMarketChangePercent": -1.5098841, "regularMarketPrice": 36.855, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "regularMarketChange": -0.5649986, "regularMarketDayRange": "36.19 - 38.9", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 489462, "fiftyTwoWeekLowChange": 7.615, "fiftyTwoWeekLowChangePercent": 0.2604309, "fiftyTwoWeekRange": "29.24 - 53.27", "fiftyTwoWeekHighChange": -16.415, "fiftyTwoWeekHighChangePercent": -0.3081472, "fiftyTwoWeekChangePercent": -10.564053, "earningsTimestamp": 1740663000, "earningsTimestampStart": 1740663000, "earningsTimestampEnd": 1740663000, "earningsCallTimestampStart": 1740663000, "earningsCallTimestampEnd": 1740663000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.34, "epsForward": -3.11, "epsCurrentYear": -2.83939, "marketState": "REGULAR", "corporateActions": [], "priceEpsCurrentYear": -12.9799, "fiftyDayAverageChange": -3.4877014, "fiftyDayAverageChangePercent": -0.08645186, "twoHundredDayAverageChange": -4.8953514, "twoHundredDayAverageChangePercent": -0.11725294, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.5 - Buy", "cryptoTradeable": false, "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]